Day: April 22, 2021

Ultragenyx Completes Successful End-of-Phase 2 Meeting with FDA and Finalizes Phase 3 Study Design for DTX301 Ornithine Transcarbamylase (OTC) Gene Therapy Program

Phase 3 Study on Track to Initiate in Second Half 2021NOVATO, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical...

The Center for Workforce Health and Performance and National Association of Worksite Health Centers Release Report to Help Employers and Insurers Manage Musculoskeletal Conditions

OAKLAND, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- Disability leaves for musculoskeletal conditions such as back pain and arthritis are...

Zogenix Presents New Data at Virtual AAN 2021 Showing Improved Executive Function in Lennox-Gastaut Syndrome (LGS) Patients Treated with FINTEPLA® (Fenfluramine) Oral Solution

LGS is one of the most challenging developmental and epileptic encephalopathies to manage because of high seizure frequency and significant...

error: Content is protected !!